Ustekinumab-stba is approved for multiple conditions, showing comparable efficacy and safety to Stelara in clinical trials. The biosimilar will be available in subcutaneous and intravenous forms, with ...

Please provide your email address to receive an email when new articles are posted on . Four biosimilars for Stelara have launched in the United States this year following legal settlements with the ...

Johnson & Johnson filed a lawsuit in a New Jersey federal court, against Samsung Bioepis for breaching its contract agreement with the company over the launch of a biosimilar to its autoimmune drug ...

The FDA has signed off on Amgen’s biosimilar version of Johnson & Johnson’s autoimmune standout Stelara. But don’t hold your breath waiting for the California biotech to launch its new product. In May ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Steqeyma as the seventh Stelara biosimilar with an expected launch date of February 2025.

Yesintek, a Stelara biosimilar, received FDA approval for IBD, plaque psoriasis, and psoriatic arthritis, with a launch expected in late 2025. Clinical trials confirmed Yesintek's equivalence to ...

J&J seeks preliminary injunction over Samsung's sublicense deal with private label provider J&J says said sublicense deal would hurt its market share Samsung Bioepis launched its biosimilar in U.S. on ...